Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 306

1.

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.

Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, Mcdonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME.

Acta Neuropathol. 2012 Oct;124(4):547-60. doi: 10.1007/s00401-012-1016-2. Epub 2012 Jul 19. Erratum in: Acta Neuropathol. 2013 Jul;126(1):159.

2.

Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.

Mur P, Rodríguez de Lope Á, Díaz-Crespo FJ, Hernández-Iglesias T, Ribalta T, Fiaño C, García JF, Rey JA, Mollejo M, Meléndez B.

J Neurooncol. 2015 May;122(3):441-50. doi: 10.1007/s11060-015-1738-9. Epub 2015 Feb 15.

PMID:
25682093
3.

Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.

Wiestler B, Capper D, Hovestadt V, Sill M, Jones DT, Hartmann C, Felsberg J, Platten M, Feiden W, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, von Deimling A, Weller M, Wick W.

Neuro Oncol. 2014 Dec;16(12):1630-8. doi: 10.1093/neuonc/nou138. Epub 2014 Jul 15.

4.

The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.

Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T.

PLoS One. 2011;6(8):e23332. doi: 10.1371/journal.pone.0023332. Epub 2011 Aug 4.

5.

MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951.

van den Bent MJ, Erdem-Eraslan L, Idbaih A, de Rooi J, Eilers PH, Spliet WG, den Dunnen WF, Tijssen C, Wesseling P, Sillevis Smitt PA, Kros JM, Gorlia T, French PJ.

Clin Cancer Res. 2013 Oct 1;19(19):5513-22. doi: 10.1158/1078-0432.CCR-13-1157. Epub 2013 Aug 15.

6.

Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM.

Shah N, Lin B, Sibenaller Z, Ryken T, Lee H, Yoon JG, Rostad S, Foltz G.

PLoS One. 2011 Jan 7;6(1):e16146. doi: 10.1371/journal.pone.0016146.

7.

A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.

Cheng W, Ren X, Cai J, Zhang C, Li M, Wang K, Liu Y, Han S, Wu A.

Oncotarget. 2015 Oct 6;6(30):29285-95. doi: 10.18632/oncotarget.4978.

8.

A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.

Malley DS, Hamoudi RA, Kocialkowski S, Pearson DM, Collins VP, Ichimura K.

Acta Neuropathol. 2011 May;121(5):651-61. doi: 10.1007/s00401-011-0803-5. Epub 2011 Feb 3.

PMID:
21287394
9.

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.

Everhard S, Tost J, El Abdalaoui H, Crinière E, Busato F, Marie Y, Gut IG, Sanson M, Mokhtari K, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Thillet J.

Neuro Oncol. 2009 Aug;11(4):348-56. doi: 10.1215/15228517-2009-001. Epub 2009 Feb 17.

10.

A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, Teepen JL, Idbaih A, Sanson M, Smitt PA, French PJ.

Clin Cancer Res. 2011 Nov 15;17(22):7148-55. doi: 10.1158/1078-0432.CCR-11-1274. Epub 2011 Sep 13.

11.

MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry.

Trabelsi S, Mama N, Ladib M, Karmeni N, Haddaji Mastouri M, Chourabi M, Mokni M, Tlili K, Krifa H, Yacoubi MT, Saad A, H'mida Ben Brahim D.

Clin Transl Oncol. 2016 Apr;18(4):391-7. doi: 10.1007/s12094-015-1381-0. Epub 2015 Aug 20.

PMID:
26289551
12.

Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.

Xie H, Tubbs R, Yang B.

Int J Clin Exp Pathol. 2015 Jan 1;8(1):636-42. eCollection 2015.

13.

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.

Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD.

Neuro Oncol. 2010 Feb;12(2):116-21. doi: 10.1093/neuonc/nop020. Epub 2009 Dec 14. Erratum in: Neuro Oncol. 2010 Jun;12(6):617.

14.

Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.

Kanemoto M, Shirahata M, Nakauma A, Nakanishi K, Taniguchi K, Kukita Y, Arakawa Y, Miyamoto S, Kato K.

BMC Cancer. 2014 Aug 30;14:641. doi: 10.1186/1471-2407-14-641.

15.

Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.

Zhang J, Yang JH, Quan J, Kang X, Wang HJ, Dai PG.

Tumour Biol. 2016 Oct;37(10):13571-13579. Epub 2016 Jul 28.

PMID:
27468718
16.

MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.

Switzeny OJ, Christmann M, Renovanz M, Giese A, Sommer C, Kaina B.

Clin Epigenetics. 2016 May 5;8:49. doi: 10.1186/s13148-016-0204-7. eCollection 2016.

17.

High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome.

Piperi C, Themistocleous MS, Papavassiliou GA, Farmaki E, Levidou G, Korkolopoulou P, Adamopoulos C, Papavassiliou AG.

Mol Med. 2010 Jan-Feb;16(1-2):1-9. doi: 10.2119/molmed.2009.00140. Epub 2009 Oct 12.

18.

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.

Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, Westphal M, Wick W, Pietsch T, Loeffler M, Weller M; German Glioma Network..

Int J Cancer. 2012 Sep 15;131(6):1342-50. doi: 10.1002/ijc.27385. Epub 2012 Jan 11.

19.

Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.

Kitange GJ, Carlson BL, Mladek AC, Decker PA, Schroeder MA, Wu W, Grogan PT, Giannini C, Ballman KV, Buckner JC, James CD, Sarkaria JN.

J Neurooncol. 2009 Mar;92(1):23-31. doi: 10.1007/s11060-008-9737-8. Epub 2008 Nov 15.

20.

Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.

Xie H, Tubbs R, Yang B.

Int J Clin Exp Pathol. 2015 Feb 1;8(2):1790-6. eCollection 2015.

Supplemental Content

Support Center